Erenumab “effective and well tolerated” as long-term treatment for migraine

Long-term results from patients with episodic migraine show erenumab reduces migraine frequency and is well tolerated. Data from a trial conducted in the USA and Germany showed that results from a double-blind study were maintained in patients who completed at least 4 years of a 5-year open-label extension.